The earnings call highlighted several positive developments, including significant revenue growth, successful partnerships, and progress toward Medicare coverage. However, challenges remain in terms of revenue recognition and high operational costs. The sentiment is cautiously optimistic with a focus on achieving Medicare coverage as a key milestone.

Company Guidance

During the Lucid Diagnostics Second Quarter 2025 Business Update Conference Call, the company provided guidance on several key metrics and strategic initiatives. Test volume for their EsoGuard product reached 2,756 tests, aligning with their target range of 2,500 to 3,000 tests per quarter, contributing to a revenue of $1.2 million, marking a 40% increase from the previous quarter. Lucid Diagnostics emphasized their strategic partnership with Hoag health system in Orange County to expand EsoGuard's reach, which involves collaboration with over 200 primary care physicians and gastroenterologists. The company also highlighted advancements in securing Medicare coverage, noting an upcoming Multi-Jurisdictional CAC meeting as a critical step towards favorable Medicare policy. Financially, Lucid reported $31.1 million in cash at the end of the quarter, with a quarterly burn rate of $10.3 million. They have a robust pipeline for cash pay and contracted programs and are actively engaging with commercial payers to expand coverage policies. The conference call underscored confidence in achieving Medicare coverage, which is anticipated to significantly impact future revenue and commercialization efforts.

Significant Revenue Growth

Revenue for the second quarter was $1.2 million, representing a 40% increase from the first quarter and matching a previous quarterly high.

Partnership with Hoag

Lucid Diagnostics launched a comprehensive EsoGuard esophageal precancer testing program in partnership with Hoag, a world-class health system in Orange County, California.

Successful Financing

An underwritten public offering netted $16.1 million, extending the company's runway well into 2026.

Highmark Blue Cross Blue Shield Coverage

Highmark Blue Cross Blue Shield positive coverage policy for EsoGuard became effective, marking the first commercial coverage policy for Lucid Diagnostics.

Positive Indicators for Medicare Coverage

Upcoming Multi-Jurisdictional CAC meeting scheduled for September 4 is seen as a strong indicator of progress towards a positive Medicare coverage policy outcome.

Lucid Diagnostics (LUCD) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

LUCD Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 17, 2025	2025 (Q3)	-0.10 / -	-0.2	―	―	―
Aug 13, 2025	2025 (Q2)	-0.11 / -0.10	-0.2	50.00% (+0.10)	―
May 14, 2025	2025 (Q1)	-0.15 / -0.16	-0.99	83.84% (+0.83)	―
Mar 24, 2025	2024 (Q4)	-0.18 / -0.19	-1.33	85.71% (+1.14)	―
Nov 13, 2024	2024 (Q3)	-0.21 / -0.20	-0.22	9.09% (+0.02)	―
Aug 12, 2024	2024 (Q2)	-0.20 / -0.20	-0.23	13.04% (+0.03)	―
May 13, 2024	2024 (Q1)	-0.24 / -0.99	-0.24	-312.50% (-0.75)	―
Mar 25, 2024	2023 (Q4)	-0.23 / -1.33	-0.33	-303.03% (-1.00)	―
Nov 13, 2023	2023 (Q3)	-0.24 / -0.22	-0.28	21.43% (+0.06)	―
Aug 14, 2023	2023 (Q2)	-0.28 / -0.23	-0.41	43.90% (+0.18)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

LUCD Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 13, 2025	$1.00	$0.98	-2.00%
May 14, 2025	$1.19	$1.28	+7.56%
Mar 24, 2025	$1.52	$1.50	-1.32%
Nov 13, 2024	$1.00	$1.05	+5.00%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Lucid Diagnostics (LUCD) report earnings?

Lucid Diagnostics (LUCD) is schdueled to report earning on Nov 17, 2025, After Close (Confirmed).

What is Lucid Diagnostics (LUCD) earnings time?

Lucid Diagnostics (LUCD) earnings time is at Nov 17, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is LUCD EPS forecast?

LUCD EPS forecast for the fiscal quarter 2025 (Q3) is -0.1.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing